Mepolizumab treatment alters the functional phenotype of eosinophils in severe eosinophilic asthma

BackgroundBlood eosinophil count is usually employed as a predictive and response biomarker for mepolizumab treatment. However, its decrease is not always associated with an improvement in asthma symptoms. The aim of this work is to study the effect of mepolizumab in the activation status and functi...

Celý popis

Podrobná bibliografie

Hlavní autoři:	Pablo Miguéns-Suárez, Laura Martelo-Vidal, Sara Vázquez-Mera, Marina Blanco-Aparicio, Uxío Calvo-Álvarez, Coral González-Fernández, Mar Mosteiro-Añón, Dolores Corbacho-Abelaira, Tamara Hermida-Valverde, Christian Calvo-Henríquez, Juan J. Nieto-Fontarigo, Francisco J. Salgado, Francisco J. González-Barcala
Médium:	Artigo
Jazyk:	Inglês
Vydáno:	Frontiers Media S.A. 2025-11-01
Edice:	Frontiers in Immunology
Témata:	anti-IL-5 mAb biologic eosinophil activation eosinophil subsets IL-5 severe asthma
On-line přístup:	https://www.frontiersin.org/articles/10.3389/fimmu.2025.1654111/full
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!